This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bausch Health (BHC) Beats Q1 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 10.64% and -2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
by Indrajit Bandyopadhyay
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
Why Is Bausch (BHC) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.
Bausch Health (BHC) Q4 Earnings Beat Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 19.82% and -0.23%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Bausch Health (BHC) Ahead of Earnings?
by Zacks Equity Research
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bausch Health (BHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2020 results.
What's in Store for Zomedica (ZOM)This Earnings Season?
by Zacks Equity Research
Zomedica (ZOM) may provide an update on Truforma commercialization progress when it reports fourth-quarter 2020 results.
What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?
by Zacks Equity Research
Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.
TEVA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.
Humana (HUM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) fourth-quarter 2020 earnings might have endured escalating COVID-related expenses, partly offset by better revenues.
Bausch Health (BHC) Dry Eye Treatment Study Enrollment Complete
by Zacks Equity Research
Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.
Why Is Bausch (BHC) Up 13.3% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.
Bausch (BHC) Begins Second Phase III Study on NOV03 for DED
by Zacks Equity Research
Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.
Should Value Investors Consider Bausch Health (BHC) Now?
by Zacks Equity Research
Let's see if Bausch Health (BHC) stock is a good choice for value-oriented investors right now from multiple angles.
Bausch's (BHC) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.
Bausch Health (BHC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 28.43% and 1.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Bausch Health (BHC)
by Zacks Equity Research
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Humana (HUM) Gears Up for Q3 Earnings: What Awaits the Stock?
by Zacks Equity Research
Humana's (HUM) third-quarter 2020 results are likely to reflect elevated expenses and lower net investment income, partially offset by a growing membership base.
Universal Health (UHS) to Report Q3 Results: What to Expect
by Zacks Equity Research
Universal Health's (UHS) third-quarter earnings results are likely to reflect depressed revenues and weak admissions.
Centene's (CNC) Q3 Earnings Improve Y/Y on High Revenues
by Zacks Equity Research
Centene's (CNC) third-quarter results reflect higher revenues and managed care membership.
Anthem (ANTM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) third-quarter earnings results are likely to reflect elevated costs and a softness in Commercial business line.
Bausch Acquires License for Myopia Solution from Eyenovia
by Zacks Equity Research
Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.